Every material Form 8-K Monte Rosa Therapeutics, Inc. has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Monte Rosa Therapeutics reported third-quarter 2026 results, with collaboration revenue of $54.4 million and net income of $3.1 million, compared with $12.8 million of revenue and a $27.1 million net loss a year earlier. The revenue increase was mainly driven by a $50.0 million Novartis milestone, and the company's nine-month results still show a net loss of $84.8 million.
Q3 2026 collaboration revenue was $54.4 million, versus $12.8 million in Q3 2025, primarily from a $50.0 million milestone tied to Novartis's Phase 2 study of MRT-6160 in Sjögren's disease.
Q3 2026 R&D expenses were $45.4 million, up from $36.7 million, mainly from increased spending on development and discovery programs.
Nine-month 2026 net loss was $84.8 million, compared with net income of $7.5 million in the first nine months of 2025.
Cash, cash equivalents, restricted cash, and marketable securities were $582.6 million as of September 30, 2026, which the company expects to support operations into 2029.
Monte Rosa Therapeutics said its Phase 1 GFORCE-1 study of MRT-8102 in 108 obese subjects with elevated cardiovascular risk showed reductions in several inflammation and plaque-related markers, with no serious adverse events reported. The filing does not include revenue, earnings or guidance, and the results come from an early-stage study. The company plans to start several Phase 2 studies, with timing running from late 2026 to the first half of 2027.
GFORCE-1 enrolled 108 subjects, randomized to MRT-8102 at 5 mg, 20 mg or 40 mg once daily, or placebo, with 4 weeks of dosing and 4 weeks of follow-up.
NEK7 degradation had a median reduction of approximately 80% to 90% across all three dose levels.
Treatment-emergent adverse events occurred in 33% of MRT-8102 participants and 30% of placebo participants; no serious adverse events were reported.
Median lipoprotein(a) fell 24%; GFORCE-2 is expected to start in H1 2027 and GEMINI-1 in Q4 2026 or Q1 2027.
Monte Rosa Therapeutics said its partner Novartis has started a Phase 2 clinical study of MRT-6160 (DDY391) in people with Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa. The payment is tied to the first patient visit, and the company is eligible for up to $2.1 billion in development, regulatory, and sales milestones under the Novartis agreement. The filing does not report revenue, earnings, or guidance.
Novartis initiated a Phase 2a/b study of MRT-6160 (DDY391) in participants with Sjögren's disease; the study is identified as NCT07737743 on ClinicalTrials.gov
Monte Rosa will receive a $50 million milestone payment from Novartis in connection with the first patient visit
Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, plus additional Phase 2 study initiation milestones
Monte Rosa will co-fund any Phase 3 development and share 30% of U.S. manufacturing and commercialization profits and losses for MRT-6160
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Monte Rosa Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →